Kornimate/medical-research-clean huggingface dataset:
a study to evaluate the efficacy and safety of two doses of pf-03654746 in adults with attention deficit hyperactivity disorder (adhd).

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the purpose of this study is to determine whether pf-03654746 is effective in the treatment of adult attention deficit hyperactivity disorder (adhd). this will be a randomized, double-blind, crossover study in which adults with adhd will receive 3 weeks of treatment with pf-03654746, either a low dose (1 mg), or flexible dose (0.50 mg titrated up to 2 mg), and 3 weeks of placebo. a washout period will separate the 2 treatment periods. participants will be required to washout of prior adhd medication before entering the study. participants will be required to come to the site for 10 visits over approximately a 10-week period.


Eligibility criteria:
inclusion criteria: subjects with a diagnosis of attention deficit hyperactivity disorder, based on clinical assessment and interview. male and female outpatients. subjects with a diagnosis of attention deficit hyperactivity disorder, based on clinical assessment and interview. female subjects must be of non-childbearing potential. exclusion criteria: evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular (including hypertension), hepatic, neurologic, or allergic disease. current or lifetime history of psychosis or bipolar disorder; any current anxiety disorder (with the exception of social or specific phobia), or substance abuse or dependence in the past 6 months. current episode of major depression or episode within the last 6 months.
the efficacy and safety of intra-oral topical ketoprofen for the treatment of acute migraine

Conditions: Migraine Disorders; Migraine Headache; Migraine; Acute Migraine

Summary: the purpose of this study is to evaluate the efficacy and safety of intra-oral topical ketoprofen for the treatment of acute migraine.


Eligibility criteria:
inclusion criteria: * established diagnosis of migraine as per ihs with aura * established diagnosis of migraine as per ihs without aura * at least 2 migraines per month * at least 18 years of age exclusion criteria: * pregnancy or lactation * other headache conditions including basilar, hemiplegic, or ophthalmoplegic migraines * chronic daily headache * allergy or sensitivity to nsaids * other severe medical conditions including gi bleeding, blood dyscrasias, thrombocytopenia

Keywords: acute migraine treatment migraine treatment migraine headache treatment
resistance exercise and cognition in people with type 1 diabetes

Conditions: type1diabetes

Summary: the aim of the current study is to determine the effects of resistance exercise on performance of the paced auditory serial addition test and the colour trails test.


Eligibility criteria:
inclusion criteria: * physician confirmed type 1 diabetes for at least 1 year * stable insulin therapy for 3 months prior to the study exclusion criteria: * bmi of 45 or higher * bp of 160/100mmhg or higher * autonomic neuropathy * severe proliferative retinopathy * joint or limb injuries preventing weight-bearing activity * autonomic neuropathy * severe proliferative retinopathy * any other medical condition that prevents participants from exercising safely.

Keywords: exercise cognition
impact of a magnetic resonance imaging (mri) scanner exclusively dedicated to emergency in the clinical management of patients presenting with diplopia or dizziness

Conditions: Stroke; Dizziness; Diplopia; MRI; Emergency Department

Summary: irm-du is a prospective observational single center study conducted in an emergency department to evaluate the impact of a mri scanner exclusively dedicated to emergency in the clinical management of patients presenting with dizziness or diplopia. the study will compare 2 strategies : after and before availability of a mri scanner dedicated to emergency. the primary endpoint is the proportion of patients with a diagnosis of stroke confirmed by imaging (mri or computed tomography (ct)) in the group "before implementation of the emergency mri scanner" and the group "after implementation of the emergency mri scanner". the hypothesis is that the availability of a mri scanner dedicated to emergency will improve the diagnosis of stroke in patients presenting with dizziness or diplopia, and will reduce emergency department stay, hospital stay and hospitalisation costs.


Eligibility criteria:
inclusion criteria: * age over 18 years * non opponent to participate * dizziness or diplopia requiring brain imaging in order to eliminate stroke exclusion criteria: * opponent to participate * pregnant women * recent cerebral trauma * potentially eligible to thrombolysis * impaired consciousness * unable to give consent
smartphone-enabled health coaching intervention for youth diagnosed with major depressive disorders

Conditions: Disorder, Major Depressive

Summary: randomized controlled trial (rct) comparing youth diagnosed with major depressive disorder treated with online mindfulness-based cognitive behavioural therapy vs. standard psychiatric care (as wait-list controls). eligible subjects will be recruited from the wait-lists of the centre for addiction and mental health. n = 168 subjects will consist of youth from first nations background (18-30 yrs) and youth from all other ethnic backgrounds stratified to two intervention groups and two wait-list control groups consisting of 50% first nations youth and 50% youth of all other ethnic backgrounds.

a high proportion (70%) of mental health problems appear before 25 yrs. and can become become long-standing, significant disorders that impair all life domains. early signs of disorder left untreated is an acute problem for canadian youth as 15-25 yrs is the most likely age-strata for diagnosable psychiatric disorders, substance dependencies and suicide. progress in youth treatments that engage the tendencies of youth to respond to online internet contact are likely to be especially strategic. in this randomized controlled trial (rct) diagnosed depressed youth are treated with online mindfulness-based cognitive behavioural therapy (mb-cbt) and standard psychiatric care or just standard psychiatric care (as wait-list controls). eligible subjects will be recruited from the wait-lists of the centre for addiction and mental health (camh), and from community-based practices and clinics proximal to camh. the consented 168 subjects will be from first nations background (18-30 yrs) and from all other ethnic backgrounds, stratified into two intervention groups and two wait-list control groups. primary outcome is self reported depression using the beck depression inventory ii while secondary outcomes include self reported anxiety (beck anxiety inventory), depression (quick inventory of depressive symptomatology, 24-item hamilton rating scale for depression (hrsd-24)), pain (brief pain inventory) mindfulness (five-facet mindfulness questionnaire) and intervention costs. if hypotheses are confirmed that youth can be effectively treated with online mb-cbt at reduced costs, effective treatment can be delivered to greater numbers with less geographic restriction.

Eligibility criteria:
inclusion criteria * 18-30 yrs * first nations background or other ethnicity * bdi-ii at mild-moderate levels (i.e., bdi-ii score ≥ 14 and \< 29 ) * diagnosis of major depressive disorder * fluent in english * diagnosis by a camh physician and diagnosis confirmed by a mini international neuropsychiatric interview exclusion criteria * \ 30 yrs * bdi-ii in severe range ≥ 29 or \< 14 * does not qualify for diagnosis of major depressive disorder or diagnosis not confirmed by mini international neuropsychiatric interview
a trial of cm-at in children with autism

Conditions: Autism

Summary: the purpose of this study is to determine whether cm-at is safe and effective in treating the core symptoms of autism.

autism is currently a significant cause of disability in the pediatric population. treatment is based upon the observation that many children with autism do not digest protein. cm-at is a proprietary enzyme that is designed as a powder taken three times a day.

Eligibility criteria:
inclusion criteria: * meets the current diagnostic and statistical manual for mental disorders (dsm-iv-tr) diagnostic criteria for autistic disorder (ad) exclusion criteria: * patient weighing \< 11kg (24.2 lbs.) * demonstrated previous allergy to porcine (pork) products * previous history of severe head trauma or stroke, seizure within one year of entering study or uncontrolled systemic disease * diagnosis of: hiv, cerebral palsy, endocrine disorder, pancreatic disease * within 30 days of starting the study, certain supplementation, chelation or dietary restriction (a 30 day washout period would be required for inclusion) * use of of any stimulant medication must be discontinued 5 days prior to entering the study. * subject must have a stable dose of ssri's for at least 30 days.

Keywords: autism
allopurinol in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis

Conditions: Endoscopic Retrograde Cholangiopancreatography

Summary: * the investigators evaluated the role of allopurinol in prevention of post-ercp pancreatitis. * 100 egyptian patients who were candidates for ercp were included and divided into two groups. group 1 (study group) included 50 patients who received two doses of allopurinol 300 mg each, 15 hours and 3 hours before ercp and group 2 (control group) included 50 patients who did not receive allopurinol prophylaxis.

a diagnosis of procedure-related pancreatitis was based on an increased serum amylase level greater than three times the upper normal limits, associated with abdominal pain requiring analgesics and persisting for at least 24 hours after the procedure.

Eligibility criteria:
inclusion criteria: * patients who were going to be subjected to ercp due to different causes exclusion criteria: * patients with clinically evident acute pancreatitis or hyperamylesemia (≥150 iu/l) before the procedure. * current or recent use of allopurinol (within the last 48 hours). * hypersensitivity to allopurinol or hydro-soluble contrast solutions. * current use of drugs with a known interaction with allopurinol, including cyclophosphamide, chlorpropamide, azathioprine, mercaptopurines, or probenecid. * nsaids intake within a week prior to assessment. * previous endoscopic or surgical sphincterotomy. * those with severe co-morbid conditions. * female patients with a known or suspected pregnancy and/or lactation.
3d endoanal ultrasound and anal fistula

Conditions: Anal Fistula

Summary: the study aims to evaluate the use of 3d endoanal ultrasound in preoperative management of anal fistula disease.


Eligibility criteria:
inclusion criteria: * anal fistula * no previous fistula procedures exclusion criteria: * previous fistula procedures * ano/rectovaginal fistula * inflammatory bowel disease * more than one internal openings

Keywords: anal fistula fistula in ano endoanal ultrasound 3d ultrasound 3d ultrasonography endoanal ultrasonography diagnostics
a phase iii trial for patients with metastatic breast cancer

Conditions: Breast Cancer; Breast Neoplasms; Cancer of the Breast

Summary: this is a phase iii randomized study between the docetaxel/gemcitabine and docetaxel/ capecitabine doublets, with crossover to the alternate agent. the experimental arm will receive gemcitabine 1000 mg/m2 intravenous (iv) over 30 minutes days 1 and 8 and docetaxel 75 mg/m2 iv day 1 over 1 hour repeated every three weeks. the comparator arm will receive docetaxel 75 mgm/m2 iv day 1 over 1 hour and oral capecitabine 1000 mg/m2 twice daily, days 1 through 14 repeated every three weeks. patients who progress on the experimental arm, will be treated with capecitabine as dosed on the comparator arm. patients who progress on the comparator arm will be treated with gemcitabine as dosed on the experimental arm.


Eligibility criteria:
inclusion criteria: * histologic or cytologic confirmation of breast cancer with locally advanced and/or metastatic disease * patients may have received prior neo-adjuvant or adjuvant taxane regimen as long as it has been greater than or equal to 6 months since completion of the regimen * patients may have had 0-1, but no more than one prior course of chemotherapy for metastatic disease * patients must have either measurable or non-measurable (evaluable) disease * prior radiation therapy allowed of less than 25% of the bone marrow exclusion criteria: * second primary malignancy (except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated at least 5 years previously with no evidence of recurrence) * parenchymal or leptomeningeal brain metastases * peripheral neuropathy greater than or equal to grade 2 * prior treatment with gemcitabine and capecitabine will not be allowed. prior treatment with a taxane in the metastatic setting will not be allowed. prior taxane therapy in the neo-adjuvant or adjuvant setting is allowed if completion of therapy greater than or equal to 6 months prior to enrollment. * active cardiac disease not controlled by therapy and/or myocardial infarction within the preceding 6 months. * concomitant herceptin is not allowed
tiotropium + olodaterol fixed dose combination (fdc) in chronic obstructive pulmonary disease (otemto 1)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the objective of this study is to assess the efficacy and safety of 12 weeks once daily treatment with orally inhaled tiotropium + olodaterol fdc (delivered by the respimat inhaler) compared with tiotropium and placebo in patients with copd.


Eligibility criteria:
inclusion criteria: * diagnosis chronic obstructive pulmonary disease * relatively stable airway obstruction with post fev1 \>=30 and \< 80% predicted normal and post fev1/ fvc \< 70% * male or female patients, 40 years of age or more * smoking history more than 10 pack years exclusion criteria: * significant diseases other than copd * history of asthma * copd exacerbation in previous 3 months * completion of pulmonary rehabilitation program within previous 6 weeks or current participation in pulmonary rehabilitation program. * pregnant or nursing women * patients unable to comply with pulmonary medication restrictions
spinal versus general anesthesia for laparoscopic cholecystectomy

Conditions: Cholecystitis; Gallbladder Diseases

Summary: the aim of this study is to compare early postoperative outcomes of unselected consecutive patients underwent laparoscopic cholecystectomy (lc) under spinal versus general anesthesia.

laparoscopic cholecystectomy (lc) is the gold standard surgical treatment of symptomatic cholecystectomy which traditionally performed under general anesthesia. laparoscopy has provided many advantages over open surgery for the patients; however, general anesthesia adversely affects patients' early postoperative quality of life (poqol). spinal anesthesia which is a less invasive technique compared to general anesthesia has many advantages regarding the poqol such as no need to wait for recovery from anesthesia, less nausea and vomiting, less or no pain at the end of surgery, no discomfort associated with intubation, early ambulation, fully awaken and oriented patient in the bed, and less anxious relatives. lc has been shown to be feasible under spinal anesthesia if performed with proper technique. there are many reports demonstrated the effectiveness and safety of lc under spinal anesthesia in selected patients. however, patients with complicated gallstone disease such as acute, gangrenous or subacute cholecystitis have been considered as unfit cases for lc under spinal anesthesia because of technical difficulties. on the other hand, spinal anesthesia has also been regarded as inappropriate for patients complying with american society for anesthesiology (asa) iii and iv due to the uncontrolled anesthesia risks. the aim of this study is to compare early postoperative outcomes of unselected consecutive patients underwent lc under spinal versus general anesthesia. if proportion of general anesthesia (pga) / proportion of spinal anesthesia (psa) denotes the proportion rate of outcomes in the general anesthesia group (gag) / spinal anesthesia group (sag), then two-sided test problem is assessed as follow: 1. null hypothesis: h0: pga = psa. there is no difference between the two anesthesia techniques in terms of primary outcomes. 2. null hypothesis: h1: pga ≠ psa there is a difference between the two anesthesia techniques in terms of primary outcomes.

Eligibility criteria:
inclusion criteria: * all patients who underwent laparoscopic cholecystectomy for symptomatic gallstone disease with no restriction for age, gender, ethnicity, disease severity, and asa grade. exclusion criteria: * patients were excluded if they underwent concurrent surgeries, had malignancy suspicion, received or converted to open surgery, and patients who were under spinal anesthesia converted to general anesthesia.

Keywords: cholecystectomy, laparoscopic spinal anesthesia general anesthesia cholecystectomy
a study evaluating biomarkers in participants with heart failure (mk-0000-344)

Conditions: Heart Failure

Summary: the aim of this 2-part study is to assess b-type natriuretic peptide (bnp) as well as other circulating and imaging biomarkers in myocardial function. part 1 assesses biomarker levels in healthy participants and participants with cardiac dysfunction. part 2 assesses bnp and other circulating biomarker levels, and performs imaging in participants with cardiac dysfunction who continued from part 1. the primary hypothesis is that compared to healthy participants, biomarker levels are elevated in participants with mild/moderate and severe cardiac dysfunction.


Eligibility criteria:
inclusion criteria: * female of reproductive potential must demonstrate non-pregnant state, and agree to use two acceptable methods of birth control * postmenopausal or surgically sterile female * have a body mass index (bmi) \>= 18 and =\< 35 kg/m\^2, inclusive * healthy participants are in general good health * participants with hf have no untreated, significant health issue from other co-morbidities, e.g. uncontrolled hypertension * is willing to undergo echocardiography, cmr, and other study assessments * participants with hf have a diagnosis of cardiomyopathy, and slight to moderate limitation of physical activity, but are comfortable at rest * participants with hf are on a stable medical therapy for hf for two weeks prior to start of part 1 * participants with hf are on a stable diuretic regimen of \>= 40 mg/day furosemide or \>= 10 mg/day torsemide for at least 2 weeks prior to start of part 1 exclusion criteria: * has any clinically significant, uncontrolled renal, endocrine (except type ii diabetes), neurological, hepatic, immunological or inflammatory disease * has a history of cancer (malignancy) * had major surgery or donated/lost approximately 500 ml of blood within 4 weeks prior to screening * participated in another investigational trial within 4 weeks prior to screening * excepting permitted medications, uses prescription, or non-prescription drugs or herbal remedies 2 weeks prior to enrollment until completion of trial * takes medications that affect bnp levels within 30 days prior to screening * undergoes high-intensity physical exercise from 1 week prior to pretrial visit until completion of trial * has implanted or embedded metal objects in body that in response to a magnetic field could cause injury * suffers from claustrophobia making them unable to undergo cmr scanning * consumes alcohol for 7 days prior to screening until completion of study * consumes excessive amounts of caffeinated beverages * uses cannabis regularly, or any illicit drugs, or has a history of drug (including alcohol) abuse within prior 12 months
evaluating the expression levels of microrna-10b in patients with gliomas

Conditions: Astrocytoma; Oligodendroglioma; Oligoastrocytoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma; Glioblastoma; Brain Tumors; Brain Cancer

Summary: micrornas (mirna) are molecular biomarkers that post-transcriptionally control target genes. deregulated mirna expression has been observed in diverse cancers. in high grade gliomas, known as glioblastomas, the investigators have identified an oncogenic mirna, mirna-10b (mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue. this study tests the hypothesis that in primary glioma samples mir-10b expression patterns will serve as a prognostic and diagnostic marker. this study will also characterize the phenotypic and genotypic diversity of glioma subclasses. furthermore, considering the critical function of anti-mir-10b in blocking established glioblastoma growth, the investigators will test in vitro the sensitivity of individual primary tumors to anti-mir-10b treatment. tumor, blood and cerebrospinal fluid samples will be obtained from patients diagnosed with gliomas over a period of two years. these samples will be examined for mir-10b expression levels. patient survival, as well as tumor grade and genotypic variations will be correlated to mir-10b expression levels.


Eligibility criteria:
inclusion/exclusion criteria: * 18 years of age * brain tumor(s) to be resected for clinical reasons. * histological pathology confirmation that tumor is of glial origin, who grade ii, iii or iv. * adequate tissue available for processing as determined by pathology. * adequate decision making ability to review, discuss and sign a consent form to allow their tumor samples to be used for future human brain tumor biology laboratory research. determination of capacity to consent is made by one of the co-investigators based on clinical assessment. * patients opting for the standard treatment regimen for their disease as well as ongoing clinical trials will be are eligible to participate in this study. standard care for newly-diagnosed glioblastomas typically consists of surgical resection followed by radiotherapy with concomitant temozolomide, followed by adjuvant temozolomide chemotherapy.

Keywords: glioblastoma mirna gbm astrocytoma